Anti-Tripeptidyl peptidase II/TPPII antibody [EPR13202] - BSA and Azide free

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Tripeptidyl peptidase II (TPPII) also known as TPP2 is a large peptidase complex that mechanistically degrades oligopeptides into tripeptides. It consists of a massive molecular complex with a molecular mass of approximately 5-6 MDa. TPPII is ubiquitously expressed in various tissues with high expression levels in the liver muscle and kidney. This complex is cytosolic and possesses unique endopeptidase and exopeptidase activities which makes it distinct in both structure and function from the proteasome.

Biological function summary

TPPII is an enzyme that plays a vital role in the regulation of intracellular protein turnover and antigen processing. It contributes to protein degradation especially when proteasome activities are inhibited or overwhelmed. TPPII operates in a complex and involves the dynamic assembly of its subunits to form a functional peptidase complex. Through its action TPPII maintains protein homeostasis and assists in generating peptides presented by MHC class I molecules important for immune surveillance.

Pathways

TPPII functions within the ubiquitin-proteasome system and the antigen presentation pathway. It acts as a backup to the proteasome ensuring continued protein degradation. TPPII interacts with proteins such as ubiquitin and E3 ligases which tag proteins for degradation. During antigen processing TPPII complements proteasome activity by processing longer peptides into shorter ones suitable for MHC class I presentation thereby interfacing with molecules like TAP and the proteasome subunits.

Associated diseases and disorders

Dysregulation of TPPII is associated with conditions such as cancer and neurodegenerative diseases. The upregulation of TPPII has been observed in several tumors implicating its role in promoting cell survival and proliferation. In cancer TPPII may interact with proteins such as p53 affecting apoptosis and cell cycle regulation. In neurodegenerative diseases altered TPPII function might influence protein aggregation and degradation pathways where it might relate with proteins like tau and amyloid-beta contributing to disease progression.